Abstract
Dehydroepiandrosterone (DHEA), the major precursor of androgens and estrogens, has several beneficial effects on the immune system, on memory function, and in modulating the effects of diabetes, obesity, and chemical carcinogenesis. Treatment of rats with DHEA influences expression of cytochrome P450 (P450) genes, including peroxisome proliferator-activated receptor α (PPARα)- and pregnane X receptor (PXR)-mediated induction of CYP4As and CYP3A23, and suppression of CYP2C11. DHEA treatment elevated the expression and activities of CYP3A4, CYP2C9, CYP2C19, and CYP2B6 in primary cultures of human hepatocytes. Induction of CYP3A4 in human hepatocytes was consistent with studies in rats, but induction of CYP2Cs was unexpected. The role of PXR in this response was studied in transient transfection assays. DHEA activated hPXR in a concentration-dependent manner. Because CYP2B6 induction by DHEA in human hepatocytes might involve either PXR or constitutive androstane receptor (CAR) activation, we performed experiments in primary hepatocytes from CAR knockout mice and observed that CAR was required for maximal induction of Cyp2b10 by DHEA. Furthermore, CAR-mediated Cyp2b10 induction by DHEA was inhibited by the inverse agonist of CAR, androstanol (5α-androstan-3α-ol). Further evidence for CAR activation was provided by cytoplasmic/nuclear transfer of CAR upon DHEA treatment. Elucidation of CAR activation and subsequent induction of CYP2B6 by DHEA presented an additional mechanism by which the sterol can modify the expression of P450s. The effect of DHEA on the activation of the xenosensors PPARα, PXR, and CAR, and the consequent potential for adverse drug/toxicant interactions should be considered in humans treated with this nutriceutical agent.
Footnotes
-
This study was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00413/05) (K.M.), Slovenian-Hungarian Inter-governmental S&T Cooperation Programme (SLO-2/04) (K.K., D.R., K.M.), the European Community (LSHGCT-2005-512096, Steroltalk) (K.K., J.-M.P., D.R., U.A.M., K.M.), the National Institutes of Health (DK54774) (R.A.P.), Agence Nationale de la Recherche JCJC-05-47810 (J.-M.P.), and the Swiss National Science Foundation (V.T., U.A.M.).
-
doi:10.1124/dmd.107.016303.
-
ABBREVIATIONS: DHEA, dehydroepiandrosterone or 5-androsten-3β-ol-17-one; androstanol, 5α-androstan-3α-ol; CAR, constitutive androstane receptor; CITCO, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime; P450, cytochrome P450; DAPI, 4′-6-diamidino-2-phenylindole; 7α-hydroxy-DHEA, 5-androsten-3β,7α-diol-17-one; 7-oxo-DHEA, 5-androsten-3β-ol-7,17-dione; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein; PPARα, peroxisome proliferator-activated receptor α; PXR, pregnane X receptor; TCPOBOP, 3,3′,5,5′-tetrachloro-1,4-bis(pyridyloxy)benzene; SR-12813, tetra-ethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; RT-PCR, reverse transcriptase-polymerase chain reaction; FAM, 5-carboxyfluorescein; XREM, xenobiotic-responsive element module; h, human.
- Received April 13, 2007.
- Accepted June 18, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|